Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology Bart SchadeMay 9, 20241 min readRead the full press release here.
Circulation Publishes 6-Month Outcomes from First-in-Human VCAS Trial of FieldForce™ Pulsed Field Ablation System: 82% Freedom from VT/VF Recurrence and 98% Reduction in Burden
Field Medical First-in-Human 6-Month Data Selected for Late-Breaking Clinical Trial at VT Symposium 2025
Field Medical Closes Oversubscribed $35 Million Series B to Advance Development of FieldForce™ Pulsed Field Ablation Platform
Comments